Celaidtx
2 known investors
Celaid Therapeutics develops hematopoietic stem cell expansion technology, including a method to replace albumin with polyvinyl alcohol and to expand human hematopoietic stem cells ex vivo in large quantities. The company applies this technology to stem cell transplantation and gene therapy for blood cancers such as leukemia and other blood and genetic diseases.
Founders & leadership
NA
Nobuyuki ArakawaCo-founder & Representative Director, President & CEO
MW
Motoo WatanabeCo-founder / Advisor (former Chairman & CSO)
HN
Hiromitsu NakauchiCo-founder
MS
Masatoshi SakuraiCo-founder
YI
Yusuke InoueDirector, COO & CFO
AU
Asako UchiyamaDirector, CDO (Chief Development Officer)
Investors · 2
Competitors · 6
by search overlap
Cellectis8 shared keywordsCellectis is a gene-editing company that uses its TALEN technology to engineer CAR T-cells from healthy donors into "off-the-shelf" allogeneic immunotherapy candidates aimed at treating cancer and potentially other diseases. It develops therapies designed to be broadly available rather than custom-made per patient.
Linkcelltx5 shared keywordsLink Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors. It works in the cancer immunotherapy space and has a strategic collaboration with Johnson & Johnson.
Kite Pharma4 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Celldex Therapeutics, Inc.4 shared keywordsCelldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Seed Tx4 shared keywordsSEED Therapeutics develops de novo molecular glue degraders for targeted protein degradation, using its RITE3 platform to match E3 ligases with disease-causing target proteins. Its lead RBM39 degrader (ST-01156) is in Phase 1 trials for Ewing sarcoma, hepatocellular carcinoma and related tumors, alongside additional oncology programs.
Cellics Therapeutics3 shared keywordsCellics Therapeutics is a therapeutics company; its website is a placeholder page providing only contact and location details, with no description of its products or focus.
Companies competing with Celaidtx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Celaidtx do?
- Celaid Therapeutics develops hematopoietic stem cell expansion technology, including a method to replace albumin with polyvinyl alcohol and to expand human hematopoietic stem cells ex vivo in large quantities. The company applies this technology to stem cell transplantation and gene therapy for blood cancers such as leukemia and other blood and genetic diseases.
- Who founded Celaidtx?
- Celaidtx was founded by Nobuyuki Arakawa, Motoo Watanabe, Hiromitsu Nakauchi, Masatoshi Sakurai.
- Who are Celaidtx's investors?
- Celaidtx's investors include Kobe University Capital, OSAKA University Venture Capital.